dpp 4 inhibitor with glp 1 DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner do not combine dpp-4 inhibitors

Atherosclerosis, MS, PD, and T2DM present a pleiotropic mechanistic progression, in which, inflammation and upstream oxidative-redox stress and ROS appear to share a common fertile soil background, and patients with diabetes experience both a preexisting and parallel-accelerated atherosclerosis, we have termed atheroscleropathy [32, 52, 55] (figure 4)

L- ,

Why were they made

You might wonder if certain nutrients cancel each other out or if taking them together could actually provide a better result for your body

Acrolein is a highly reactive genotoxin, with an equivalent mutagenic potency to formaldehyde, raising concerns about this metabolic process [71, 159]